Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 3/20 | 0.51 |
| ▸ | ACHE | P22303 | 3/20 | 0.51 |
| ▸ | BACE1 | P56817 | 3/20 | 0.51 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | FABP6 | P51161 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20267493 | 1.00 | GRIN2B (0.56) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| SCHEMBL20282266 | 1.00 | GRIN2B (0.56) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| SCHEMBL658055 | 0.93 | GRIN2B (0.62) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| Hydrochloric Acid SCHEMBL5238529 | 0.91 | GRIN2B (0.61) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| Methylene Chloride SCHEMBL27437439 | 0.88 | GRIN2B (0.57) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| SCHEMBL2687312 | 0.87 | SLC6A2 (0.52) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| SCHEMBL994345 | 0.87 | SLC6A2 (0.52) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| SCHEMBL2954218 | 0.84 | GRIN2B (0.69) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| SCHEMBL4173336 | 0.84 | GRIN2B (0.69) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| SCHEMBL433970 | 0.84 | GRIN2B (0.69) | GRIN2BMEN1KMT2ARAB9ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110248946-B | Azepan inhibitors of the Menin-MLL interaction | 詹森药业有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-11530226-B2 | Azepane inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-20 | — | — | US | disclosed |
| EP-3555103-B1 | AZEPANE INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-22 | — | — | EP | disclosed |
| EP-3555103-B1 | AZEPANE INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-22 | — | — | EP | disclosed |
| US-20200339594-A1 | Azepane Inhibitors Of Menin-MLL Interaction | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-29 | — | — | US | disclosed |
| EP-3555103-A1 | AZEPANE INHIBITORS OF MENIN-MLL INTERACTION | Janssen Pharmaceutica NV (BE) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018109088-A1 | AZEPANE INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018109088-A1 | AZEPANE INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-21 | — | — | WO | disclosed |
| EP-1963285-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067629-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530226-B2 | Azepane inhibitors of menin-MLL interaction | MEN1, MLLT1, BMI1 | GRIN2B 2576/4885MEN1 1/4885KMT2A 31/4885 |
| US-20200339594-A1 | Azepane Inhibitors Of Menin-MLL Interaction | MEN1, MLLT1, BMI1 | GRIN2B 2576/4885MEN1 1/4885KMT2A 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.